18F-FDG PET显像在神经退行性痴呆性疾病中的应用:对亚型分类、新兴疾病类别及伴共病的混合性痴呆的洞见
本文综述18F-FDG PET在痴呆研究及临床中的应用,涵盖葡萄糖代谢的细胞机制、统计参数图可视化代谢改变,以及阿尔茨海默病、额颞叶痴呆、路易体痴呆的鉴别已成为标准实践;并讨论额颞叶变性亚型分类、新识别的病理实体及混合性痴呆的解读演变。
要点
- 18F-FDG PET可敏感检测神经退行性变所致的神经元活动改变,表现为脑内FDG摄取改变。
- 阿尔茨海默病、额颞叶痴呆与路易体痴呆的鉴别诊断已成为18F-FDG PET的标准实践。
- 解读正从二分诊断转向判定最能解释症状的最主要潜在病理,以指导照护。
核心结论
- 18F-FDG PET解读正从传统的阿尔茨海默病对额颞叶痴呆(或路易体痴呆)二分诊断,转向判定最能解释患者症状的最主要潜在病理,以指导照护。
- 18F-FDG PET是相对低成本且广泛可及的影像模态,可在单次检查中评估多种神经退行性疾病,仍是临床痴呆评估的主力工具。
研究设计与样本
- 本文为综述,回顾18F-FDG PET用于痴呆研究与临床应用的相关文献,涵盖葡萄糖代谢机制、统计参数图可视化及疾病亚型分类进展。
主要发现
- FDG为葡萄糖类似物,经葡萄糖转运体进入脑内,在涉及星形胶质细胞与神经元的协同过程中被代谢,其确切细胞机制仍在研究中。
- 不同神经退行性疾病累及不同脑区,可表现为PET上FDG摄取改变,其空间模式与严重程度可通过统计参数图技术可重复地可视化。
- 额颞叶变性在临床上被亚分类为行为变异型额颞叶痴呆;原发性进行性失语含语义型、非流利型与少词型3个亚型;以及包括进行性核上性麻痹与皮质基底节变性在内的运动障碍。
- 新识别或重新定义的疾病类别包括边缘优势年龄相关TDP-43脑病、海马硬化、原发性年龄相关tau病及嗜银颗粒病,已成为分子影像研究的焦点。
- 近期病理研究揭示混合性痴呆(病理重叠与共存)患病率高,尤其在老年人中。
临床怎么用
- 18F-FDG PET仍是临床痴呆评估的主力工具,可在单次检查中帮助评估多种神经退行性疾病。
- 解读18F-FDG PET时需将额颞叶变性亚型分类、新识别的病理实体及混合性痴呆的发现整合入现代解读框架。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the invention of 18F-FDG as a neurochemical tracer in the 1970s, 18F-FDG PET has been used extensively for dementia research and clinical applications. FDG, a glucose analog, is transported into the brain via glucose transporters and metabolized in a concerted process involving astrocytes and neurons. Although the exact cellular mechanisms of glucose consumption are still under investigation, 18F-FDG PET can sensitively detect altered neuronal activity due to neurodegeneration. Various neurodegenerative disorders affect different areas of the brain, which can be depicted as altered 18F-FDG uptake by PET. The spatial patterns and severity of such changes can be reproducibly visualized by statistical mapping technology, which has become widely available in the clinic. The differentiation of 3 major neurodegenerative disorders by 18F-FDG PET, Alzheimer disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), has become standard practice. As the nosology of FTD evolves, frontotemporal lobar degeneration, the umbrella term for pathology affecting the frontal and temporal lobes, has been subclassified clinically into behavioral variant FTD; primary progressive aphasia with 3 subtypes, semantic, nonfluent, and logopenic variants; and movement disorders including progressive supranuclear palsy and corticobasal degeneration. Each of these subtypes is associated with differential 18F-FDG PET findings. The discovery of new pathologic markers and clinicopathologic correlations via larger autopsy series have led to newly recognized or redefined disease categories, such as limbic-predominant age-related TDP-43 encephalopathy, hippocampus sclerosis, primary age-related tauopathy, and argyrophilic grain disease, which have become a focus of investigations by molecular imaging. These findings need to be integrated into the modern interpretation of 18F-FDG PET. Recent pathologic investigations also have revealed a high prevalence, particularly in the elderly, of mixed dementia with overlapping and coexisting pathologies. The interpretation of 18F-FDG PET is evolving from a traditional dichotomous diagnosis of AD versus FTD (or DLB) to a determination of the most predominant underlying pathology that would best explain the patient's symptoms, for the purpose of care guidance. 18F-FDG PET is a relatively low cost and widely available imaging modality that can help assess various neurodegenerative disorders in a single test and remains the workhorse in clinical dementia evaluation.
引用
- Minoshima S, Cross D, Thientunyakit T, et al. 18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. J Nucl Med. 2022. PMID: 35649653. doi:10.2967/jnumed.121.263194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。